DOI:

SR200 MyoCath™ percutaneous microimplant delivery system

Howard Leonhardt*, Richard Spencer

Description

The SR200 MyoCath™ is a endoventricular needle-injection catheter utilizing catheter tip deflection technology and a adjustable depth, spring-loaded needle to provide multiple and precise delivery of biologic injectate to targeted myocardium.

History

MyoCath™ intellectual property was secured in 1999 and 2000. Initial prototypes were created and design was finalized in 2000. Bench testing, design control testing, biocompatibility/toxicity testing, thrombogenicity testing, in vitro testing and in vivo testing were all completed in 2001. MyoCath™ is manufactured in an ISO certified, class 100,000 controlled environment room and has been in clinical use since 2002.

Technical specifications

Indication for use

MyoCath™ is an investigational device indicated for injecting an aqueous solution or suspension, for diagnostic or therapeutic purposes, into internal tissues or organs.

Tips and tricks for delivery (use)

– Use of a steerable guidewire is not required.

– Slight deflection of the catheter tip facilitates crossing the aortic valve when performing endoventricular injections.

– A 9F guide catheter can be used if additional back-up support is required to reach difficult areas (i.e. septal) of the left ventricle.

– During long procedures, flushing the catheter with cold saline restores torquability and back-up support.

– Using deliberate force to extend the needle and infusing the injectate slowly over several seconds helps to optimize channel creation and injectate retention in scarred areas of myocardium.

– PVCs and tactile feel will confirm presence of the needle against the myocardial wall.

– Mixing injectate with non-ionic contrast enhances visualization of injectate retention under fluoroscopy.

Preclinical experience

As part of the design validation effort, Bioheart, Inc. performed ten in vivo studies in the porcine model to assess performance and ease of use of the MyoCath™ in the hands of a number of experienced interventional cardiologists. The primary objective was to ensure the design is suitable for its intended use under simulated conditions in the animal model. Physicians rated the performance of the device using the following metrics:

– Device preparation

– Ease of access

– Ease of placement

– Needle core advancement / retraction

– Needle insertion / removal

– Device injection

– Device visualization

– Ease of removal

– Thrombogenicity

– Device integrity

– Overall performance

– Standard anticoagulation regime

– Comparison with standard practices

Overall, the physicians rated the MyoCath™ favorably and reported it performed in an acceptable manner.

Clinical experience

The MyoCath™ has been used in 25 clinical cases to-date. All clinical cases involved injections in chronically infracted left ventricles (septal, anterior and posterior locations were targeted). No adverse events related to MyoCath™ have ever been reported, and feedback captured from physicians following completion of these cases was highly positive.

Volume 1 Number 4
Feb 20, 2006
Volume 1 Number 4
View full issue


Key metrics

Suggested by Cory

Expert Review

10.4244/EIJ-D-25-00201 Oct 10, 2025
Drug-coated balloons for coronary bifurcation lesions
Fezzi S et al
free

Editorial

10.4244/EIJ-E-25-00040 Oct 6, 2025
Photon-counting computed tomography for stent assessment
Andreini D and Di Mario C
free

Editorial

10.4244/EIJ-E-25-00042 Oct 6, 2025
Seeing is believing
Daemen J and Sadowski K
free

Editorial

10.4244/EIJ-E-25-00044 Oct 6, 2025
Just tap it in... stent optimisation in TAVI
Mylotte D and Thaddeus Soh B
free

Research Correspondence

10.4244/EIJ-D-25-00139 Oct 6, 2025
In-depth, patient-level analysis of clinical events in the NOTION-2 trial
Khokhar A et al

Flashlight

10.4244/EIJ-D-24-01165 Oct 6, 2025
Transcatheter tricuspid valve-in-ring following bicaval valve degeneration
Asmarats L et al

Original Research

10.4244/EIJ-D-25-00307 Oct 6, 2025
Impact of clinical risk characteristics on the prognostic value of high-risk plaques
Volleberg R et al
Trending articles
317.8

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
108.3

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
96.8

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
91.6

Image – Interventional flashlight

10.4244/EIJ-D-22-00344 Aug 5, 2022
First dedicated transcatheter leaflet splitting device: the ShortCut device
Tchétché D et al
free
68.05

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved